IntelGenx Technologies Corp. (IGXT)
OTCMKTS: IGXT · Delayed Price · USD
0.170
-0.003 (-2.02%)
Jul 26, 2024, 4:00 PM EDT - Market closed
IntelGenx Technologies Employees
As of December 31, 2019, IntelGenx Technologies had 51 total employees, including 48 full-time and 3 part-time employees. The number of employees increased by 9 or 21.43% compared to the previous year.
Employees
51
Change (1Y)
9
Growth (1Y)
21.43%
Revenue / Employee
$20,608
Profits / Employee
-$216,275
Market Cap
29.69M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
IGXT News
- 7 days ago - IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process - GlobeNewsWire
- 24 days ago - IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease - GlobeNewsWire
- 6 weeks ago - IntelGenx Announces Initiation of the Sale and Investment Solicitation Process - GlobeNewsWire
- 2 months ago - IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process - GlobeNewsWire
- 2 months ago - IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives - GlobeNewsWire
- 2 months ago - IntelGenx Announces Voting Results on Election of Directors - GlobeNewsWire
- 3 months ago - IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical Trial - GlobeNewsWire
- 4 months ago - IntelGenx Updates Status of Buprenorphine Buccal Film ANDA - GlobeNewsWire